APROGEN Biologics Osong cGMP Plant

With the gross floor area of approximately 46,000㎡, APROGEN Biologics Osong Current Good Manufacturing Practice (cGMP) Plant, which consists of one basement level and four ground floors, manufactures biosimilar products. 

With the completion of this plant, APROGEN Biologics secured a facility to produce 2,500kg of biosimilar products, which is the third largest in Korea following Samsung Biologics and Celltrion, and the fifth in the world. With this achievement, APROGEN Biologics prepared a foundation for global market entry. 

Currently, the production line is under a test production process. It is expected that the plant will commence full-scale commercial production in 2022. The cGMP certification of the U.S. Food and Drug Administration (FDA), which APROGEN Biologics plans to obtain, requires fulfillment of a very strict set of criteria. Having designed and constructed the biosimilar plant of APROGEN Biologics, POSCO E&C has provided support in validation for cGMP certification. We are therefore leading the industry in the bioengineering and pharmaceutical fields. 

We have successfully completed not only the construction of APROGN Biologics’ culture media production lines 1 and 2, but also extension of lines 3 and 4. With the construction ability to faithfully reflect customer’s needs, POSCO E&C has won a contract for a high-tech R&D center of Celltrion, the second-ranking biosimilar maker in Korea, and is currently building the facility. 

  • Period
    Period
    2016.07 - 2018.07
  • Place of order
    Place of order
    Aprogen Biologics Inc.
  • Construction details
    Construction details
    Suite 1&2
    - Supply scope EPC
    * Design: 2014 – 2016
    * Construction: 2016 – 2018
    - Gross floor area: 45,927㎡
    - 1 basement level–4 ground floors
    - Reinforced concrete,
    steel frame construction

    Suite 3&4 (2019–2020)
  • Location
    Location
    Chungju, Korea

Personal Data Processing Policy Legal Disclaimer

CCTV Operation policy